HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration

Página do item simplificado
dc.citation.issue3
dc.citation.volume76
dc.contributor.authorJiamsakul, Awachana
dc.contributor.authorKariminia, Azar
dc.contributor.authorAlthoff, Keri N.
dc.contributor.authorCesar, Carina
dc.contributor.authorCortes, Claudia P.
dc.contributor.authorDavies, Mary-Ann
dc.contributor.authorViet Chau Do
dc.contributor.authorEley, Brian
dc.contributor.authorGill, John
dc.contributor.authorKumarasamy, Nagalingeswaran
dc.contributor.authorMachado, Daisy Maria [UNIFESP]
dc.contributor.authorMoore, Richard
dc.contributor.authorProzesky, Hans
dc.contributor.authorZaniewski, Elizabeth
dc.contributor.authorLaw, Matthew
dc.coveragePhiladelphia
dc.date.accessioned2020-09-01T13:21:25Z
dc.date.available2020-09-01T13:21:25Z
dc.date.issued2017
dc.description.abstractBackground: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90: 90: 90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. Methods: Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/ mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. Results: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count preART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. Conclusions: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infected patients of all age groups.en
dc.description.affiliationUNSW, Kirby Inst, Sydney, NSW 2052, Australia
dc.description.affiliationJohns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
dc.description.affiliationFdn Huesped, Buenos Aires, DF, Argentina
dc.description.affiliationUniv Chile, Sch Med, Santiago, Chile
dc.description.affiliationFdn Arriaran, Santiago, Chile
dc.description.affiliationUniv Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa
dc.description.affiliationChildrens Hosp 2, Ho Chi Minh City, Vietnam
dc.description.affiliationUniv Cape Town, Dept Paediat & Child Hlth, Cape Town, South Africa
dc.description.affiliationUniv Calgary, Calgary, AB, Canada
dc.description.affiliationYRGCARE Med Ctr, Madras, Tamil Nadu, India
dc.description.affiliationUniv Fed Sao Paulo, Pediat Infect Dis Div, Escola Paulista Med, Sao Paulo, Brazil
dc.description.affiliationJohns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA
dc.description.affiliationUniv Stellenbosch, Dept Med, Div Infect Dis, Cape Town, South Africa
dc.description.affiliationTygerberg Hosp, Cape Town, South Africa
dc.description.affiliationUniv Bern, Inst Social & Prevent Med, Bern, Switzerland
dc.description.affiliationUnifespUniv Fed Sao Paulo, Pediat Infect Dis Div, Escola Paulista Med, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipU.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases
dc.description.sponsorshipEunice Kennedy Shriver National Institute of Child Health and Human Development
dc.description.sponsorshipNational Cancer Institute
dc.description.sponsorshipCenters for Disease Control and Prevention, USA
dc.description.sponsorshipAgency for Healthcare Research and Quality, USA
dc.description.sponsorshipHealth Resources and Services Administration, USA
dc.description.sponsorshipCanadian Institutes of Health Research, Canada
dc.description.sponsorshipOntario Ministry of Health and Long Term Care
dc.description.sponsorshipGovernment of Alberta, Canada
dc.description.sponsorshipIntramural Research Program of the National Cancer Institute
dc.description.sponsorshipAustralian Government Department of Health and Ageing
dc.description.sponsorshipIDNCI: U01AI035004
dc.description.sponsorshipIDNCI: U01AI035039
dc.description.sponsorshipIDNCI: U01AI035040
dc.description.sponsorshipIDNCI: U01AI035041
dc.description.sponsorshipIDNCI: U01AI035042
dc.description.sponsorshipIDNCI: U01AI037613
dc.description.sponsorshipIDNCI: U01AI037984
dc.description.sponsorshipIDNCI: U01AI038855
dc.description.sponsorshipIDNCI: U01AI038858
dc.description.sponsorshipIDNCI: U01AI042590
dc.description.sponsorshipIDNCI: U01AI068634
dc.description.sponsorshipIDNCI: U01AI068636
dc.description.sponsorshipIDNCI: U01AI069432
dc.description.sponsorshipIDNCI: U01AI069434
dc.description.sponsorshipIDCenters for Disease Control and Prevention, USA: CDC-200-2006-18797
dc.description.sponsorshipIDCenters for Disease Control and Prevention, USA: CDC-200-2015-63931
dc.description.sponsorshipIDAgency for Healthcare Research and Quality, USA: 90047713
dc.description.sponsorshipIDHealth Resources and Services Administration, USA: 90051652
dc.description.sponsorshipIDCanadian Institutes of Health Research, Canada: CBR-86906
dc.description.sponsorshipIDCanadian Institutes of Health Research, Canada: CBR-94036
dc.description.sponsorshipIDCanadian Institutes of Health Research, Canada: HCP-97105
dc.description.sponsorshipIDCanadian Institutes of Health Research, Canada: TGF-96118
dc.description.sponsorshipIDNCI: P30AI027757
dc.description.sponsorshipIDNCI: P30AI027763
dc.description.sponsorshipIDNCI: P30AI027767
dc.description.sponsorshipIDNCI: P30AI036219
dc.description.sponsorshipIDNCI: P30AI050410
dc.description.sponsorshipIDNCI: P30AI094189
dc.description.sponsorshipIDNCI: P30AI110527
dc.description.sponsorshipIDNCI: P30MH62246
dc.description.sponsorshipIDNCI: R01AA016893
dc.description.sponsorshipIDNCI: R01CA165937
dc.description.sponsorshipIDNCI: R01DA004334
dc.description.sponsorshipIDNCI: R01DA011602
dc.description.sponsorshipIDNCI: R01DA012568
dc.description.sponsorshipIDNCI: R24AI067039
dc.description.sponsorshipIDNCI: U01AA013566
dc.description.sponsorshipIDNCI: U01AA020790
dc.description.sponsorshipIDNCI: U01AI1031834
dc.description.sponsorshipIDNCI: U01AI034989
dc.description.sponsorshipIDNCI: U01AI034993
dc.description.sponsorshipIDNCI: U01AI034994
dc.description.sponsorshipIDNCI: M01RR000052
dc.description.sponsorshipIDNCI: U54MD007587
dc.description.sponsorshipIDNCI: UL1RR024131
dc.description.sponsorshipIDNCI: UL1TR000004
dc.description.sponsorshipIDNCI: UL1TR000083
dc.description.sponsorshipIDNCI: UL1TR000454
dc.description.sponsorshipIDNCI: UM1AI035043
dc.description.sponsorshipIDNCI: Z01CP010214
dc.description.sponsorshipIDNCI: Z01CP010176
dc.description.sponsorshipIDNCI: U01AI069907
dc.description.sponsorshipIDNCI: U01AI069923
dc.description.sponsorshipIDNCI: U01AI069924
dc.description.sponsorshipIDNCI: U01AI069918
dc.description.sponsorshipIDNCI: F31DA037788
dc.description.sponsorshipIDNCI: G12MD007583
dc.description.sponsorshipIDNCI: K01A1093197
dc.description.sponsorshipIDNCI: K23EY013707
dc.description.sponsorshipIDNCI: K24DA000432
dc.description.sponsorshipIDNCI: K24AI065298
dc.description.sponsorshipIDNCI: KL2TR000421
dc.description.sponsorshipIDNCI: N02CP055504
dc.description.sponsorshipIDNCI: U01AI103390
dc.description.sponsorshipIDNCI: U01AI103397
dc.description.sponsorshipIDNCI: U01AI103401
dc.description.sponsorshipIDNCI: U01AI103408
dc.description.sponsorshipIDNCI: U01DA036935
dc.description.sponsorshipIDNCI: U01HD032632
dc.description.sponsorshipIDNCI: U10EY008057
dc.description.sponsorshipIDNCI: U10EY008052
dc.description.sponsorshipIDNCI: U10EY008067
dc.description.sponsorshipIDNCI: U24AA020794
dc.format.extent319-329
dc.identifierhttps://doi.org/10.1097/QAI.0000000000001499
dc.identifier.citationJaids-Journal Of Acquired Immune Deficiency Syndromes. Philadelphia, v. 76, n. 3, p. 319-329, 2017.
dc.identifier.doi10.1097/QAI.0000000000001499
dc.identifier.issn1525-4135
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/58250
dc.identifier.wosWOS:000416721800019
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJaids-Journal Of Acquired Immune Deficiency Syndromes
dc.relation.ispartofAustralasian HIV and AIDS Conference
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHIVen
dc.subjectsuppressionen
dc.subjectpaediatricsen
dc.subjectadultsen
dc.subjectIeDEAen
dc.titleHIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaborationen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos